Goldman Sachs Upgrades Waters; Downgrades Agilent, Genomic Health | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Agilent Technologies and Genomic Health, but upgraded Waters.

The changes to the three firms' ratings are part of a "recalibrating" of the investment bank's Life Science Tools portfolio in light of tighter credit in China and an "underappreciated risk" of renewed austerity as the US Fiscal Year 2014 budget and debt ceiling "come back into focus," analyst Isaac Ro said in a research report.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.